Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Sees Large Decrease in Short Interest

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 67,935 shares, a decrease of 35.6% from the January 15th total of 105,482 shares. Based on an average trading volume of 97,005 shares, the short-interest ratio is presently 0.7 days. Approximately 1.4% of the shares of the stock are short sold. Approximately 1.4% of the shares of the stock are short sold. Based on an average trading volume of 97,005 shares, the short-interest ratio is presently 0.7 days.

Institutional Investors Weigh In On Evaxion A/S

Several hedge funds and other institutional investors have recently made changes to their positions in EVAX. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Evaxion A/S during the fourth quarter worth $38,000. Wesbanco Bank Inc. acquired a new stake in Evaxion A/S in the fourth quarter worth about $48,000. Finally, SmartHarvest Portfolios LLC bought a new stake in Evaxion A/S during the 4th quarter worth about $72,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EVAX has been the topic of several recent analyst reports. Jones Trading upgraded shares of Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. Lake Street Capital lifted their price target on shares of Evaxion A/S from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, October 20th. Edward Jones assumed coverage on shares of Evaxion A/S in a research note on Thursday, October 30th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Monday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

Evaxion A/S Stock Performance

Shares of NASDAQ EVAX traded up $0.15 during trading on Friday, reaching $3.34. The company had a trading volume of 22,315 shares, compared to its average volume of 71,489. Evaxion A/S has a 52 week low of $1.20 and a 52 week high of $12.15. The business’s 50 day moving average price is $4.62 and its 200-day moving average price is $4.58. The stock has a market cap of $27.86 million, a PE ratio of -8.56 and a beta of 0.29.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.